一种与衰老相关的新型lncRNA特征用于预测骨髓瘤的预后
Yi He1, Xiao Huang2, Yajie Ma3
1Department of Mini-Invasive Spinal Surgery, The Third People's Hospital of Henan Province, Zhengzhou, 450006, Henan, China.
Scientific reports
|January 16, 2024
概括
研究人员确定了5个与衰老相关的生存 lncRNA签名,以预测骨髓瘤 (OS) 患者的结果. 这种特征与瘤微环境和免疫细胞透相关,为OS治疗提供了新的见解.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 骨髓瘤 (OS) 是一个常见的青少年骨瘤,与衰老的联系不清楚.
- 目前对OS的准确预后生物标志物有限.
研究的目的:
- 为了确定与衰老相关的生存 lncRNAs (AASRs) 用于OS预后.
- 开发和验证骨髓瘤的预后签名.
主要方法:
- 使用TCGA和人类衰老基因组资源数据进行生物信息学分析.
- 单变Cox,LASSO-Cox和卡普兰-梅尔生存分析.
- 在体外实验中研究UNC5B-AS1.1.的作用.
主要成果:
- 确定了与OS患者生存相关的10个AASR,导致了5-AASR签名.
- 签名将患者分为高风险 (预后更差) 和低风险 (预后更好) 组.
- 预后特征与瘤微环境和免疫细胞透相关,包括CD8+ T细胞.
结论:
- 一个5-AASR签名有效地预测骨髓瘤患者的整体存活率.
- UNC5B-AS1可能通过抑制细胞衰老和亡来促进OS的进展.
- 这些发现为骨髓瘤提供了新的治疗策略.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K